清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Clinical efficacy and safety of CIK plus radiotherapy for lung cancer: A meta-analysis of 16 randomized controlled trials

医学 肺癌 荟萃分析 内科学 随机对照试验 临床试验 放射治疗 肿瘤科 不利影响 细胞因子诱导的杀伤细胞 免疫学 CD8型 免疫系统 CD3型
作者
Zheng Xiao,Cheng-Qiong Wang,Ming-hua Zhou,Nana Li,Shiyu Liu,Yue-juan He,Yuzhi Wang,Jihong Feng,Xinsheng Yao,Ling Chen,Bin Ma,Song Yu,Xian‐Tao Zeng,Chengwen Li,Jie Ding
出处
期刊:International Immunopharmacology [Elsevier]
卷期号:61: 363-375 被引量:19
标识
DOI:10.1016/j.intimp.2018.06.012
摘要

Cytokine-induced killer cells (CIK) therapy is the most commonly used cellular immunotherapy. The CIK plus radiotherapy was clinically used in a wide range of treatment, but the efficacy of their combination against lung cancer is not clear yet. Therefore, we systematically evaluated all the related studies to reveal the combination's clinical efficacy and safety in lung cancer. We collected all the studies about CIK plus radiotherapy for lung cancer in Medline, Embase, Web of Science (ISI), China National Knowledge Infrastructure Database (CNKI), Chinese Scientific Journals Full-Text Database (VIP), Wanfang Database, China Biological Medicine Database (CBM) and Cochrane Central Register of Controlled Trials (CENTRAL), Chinese clinical trial registry (Chi-CTR), WHO International Clinical Trials Registry Platform (WHO-ICTRP) and US-clinical trials (March 2017). We evaluated their bias risk according to the Cochrane evaluation handbook of randomized controlled trials (RCTs), extracted all the data, and synthesized the data using meta analysis. We included 16 RCTs involving 1197 patients with lung cancer, and most trials had unclear risk of bias. Meta-analysis showed that CIK therapy could increase the objective response rate (ORR) (1.32, 1.21 to 1.44), the disease control rate (DCR) (1.13, 1.04 to 1.23), the 1-year overall survival (OS) rate (1.38, 1.16 to 1.63) and the 2-year OS rate (1.23, 1.11 to 1.35). DCs-CIK cells increased the 3-year OS rate (1.66, 1.20 to 2.29). DCs-CIK therapy could increase the CD3+T cells (2.27, 1.47 to 3.06), CD4+T cells (1.28, 0.74 to 1.81), NK cells (2.04, 0.74 to 3.33) and CD4+/CD8+ T cells ratio (1.20, 0.64 to 1.76) and decrease the CD8+T cells (−0.84, −1.60 to −0.08). CIK plus radiotherapy had lower risk of leukopenia (0.85, 0.76 to 0.95) and higher risk of fever (5.50, 2.71 to 11.17) than that of radiotherapy alone. Subgroup analysis showed that CIK plus radiotherapy, mainly three dimensional conformal radiotherapy (3D-CRT) could increase the ORR, DCR, 1- and 2- year OS rate in non-small cell lung cancer (NSCLC), and only DCR in small cell lung cancer (SCLC). Compared with CIK plus pure radiotherapy, except for the ORR, DCR, 1-year OS rate, CIK plus chemoradiotherapy could still increase the 2-year OS rate. DCs-CIK could increase the ORR, DCR, 1- and 2-year OS rate, CIK cells could only increase the ORR and the 1-year OS rate. CIK plus radiotherapy can improve the clinical response, OS and PFS in lung cancer. It may have low risk of leukopenia and high risk of fever. CIK plus chemoradiotherapy, mainly 3D-CRT can improve the clinical response, OS and PFS in NSCLC. DCs-CIK cells can improve the 1-, 2- and 3-year OS rate, and the 1- and 2-year PFS rate, and CIK cells only improve the 1-year OS rate. DCs-CIK cells can repair the antitumor immunity.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
eden完成签到,获得积分10
2秒前
小奋青完成签到 ,获得积分10
17秒前
tjfwg完成签到,获得积分10
19秒前
33秒前
燕山堂完成签到 ,获得积分10
37秒前
Frank发布了新的文献求助10
38秒前
wayne完成签到 ,获得积分10
47秒前
50秒前
djf点儿完成签到 ,获得积分10
1分钟前
顾矜应助朴实的耳机采纳,获得10
1分钟前
扬帆起航完成签到 ,获得积分10
1分钟前
tmrrrrrr完成签到 ,获得积分10
1分钟前
会扎针的小张完成签到,获得积分10
1分钟前
2分钟前
Sunny完成签到 ,获得积分10
2分钟前
虚幻的尔竹完成签到 ,获得积分10
2分钟前
2分钟前
背书强完成签到 ,获得积分10
2分钟前
火花完成签到 ,获得积分10
2分钟前
小西完成签到 ,获得积分10
2分钟前
2分钟前
zz完成签到 ,获得积分10
2分钟前
wefor完成签到 ,获得积分10
2分钟前
迷人的沛山完成签到 ,获得积分10
2分钟前
申木完成签到 ,获得积分10
3分钟前
段采萱完成签到 ,获得积分10
3分钟前
黄花菜完成签到 ,获得积分10
3分钟前
风不尽,树不静完成签到 ,获得积分10
3分钟前
3分钟前
fff发布了新的文献求助10
3分钟前
空曲完成签到 ,获得积分10
3分钟前
LELE完成签到 ,获得积分10
4分钟前
王磊完成签到 ,获得积分10
4分钟前
emxzemxz完成签到 ,获得积分10
4分钟前
xun完成签到,获得积分10
4分钟前
焚心结完成签到 ,获得积分10
4分钟前
AUGKING27完成签到 ,获得积分10
4分钟前
秋子骞完成签到 ,获得积分10
5分钟前
su完成签到 ,获得积分10
5分钟前
大大蕾完成签到 ,获得积分10
5分钟前
高分求助中
Sustainability in Tides Chemistry 1500
Handbook of the Mammals of the World – Volume 3: Primates 805
拟南芥模式识别受体参与调控抗病蛋白介导的ETI免疫反应的机制研究 550
Gerard de Lairesse : an artist between stage and studio 500
Digging and Dealing in Eighteenth-Century Rome 500
Queer Politics in Times of New Authoritarianisms: Popular Culture in South Asia 500
Manual of Sewer Condition Classification 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3068236
求助须知:如何正确求助?哪些是违规求助? 2722176
关于积分的说明 7476072
捐赠科研通 2369138
什么是DOI,文献DOI怎么找? 1256228
科研通“疑难数据库(出版商)”最低求助积分说明 609518
版权声明 596835